Zacks Research Has Bullish Forecast for CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a report issued on Tuesday, March 4th. Zacks Research analyst R. Department now anticipates that the company will earn ($1.61) per share for the quarter, up from their prior forecast of ($1.65). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.42) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.90) EPS, Q1 2026 earnings at ($1.46) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($5.16) EPS.

A number of other brokerages have also commented on CRSP. Bank of America dropped their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group lowered their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Needham & Company LLC restated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Truist Financial upped their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus lowered their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $73.11.

Remove Ads

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded up $2.22 during trading hours on Thursday, reaching $45.53. The stock had a trading volume of 1,884,937 shares, compared to its average volume of 2,267,393. The stock has a fifty day moving average of $42.79 and a 200 day moving average of $45.77. The stock has a market cap of $3.91 billion, a P/E ratio of -10.42 and a beta of 1.77. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $81.73.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

Insider Activity at CRISPR Therapeutics

In other news, Director John Greene acquired 7,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the purchase, the director now owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CRSP. Wood Tarver Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter worth $30,000. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter worth $36,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter worth $39,000. Western Pacific Wealth Management LP increased its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth $40,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.